Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | Director | September 15, 2026 | September 17, 2026 |
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Director | August 01, 2022 | August 03, 2022 |
| uniQure N.V.QURE · Entity 4162 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 1,000 · Balance 1,000 Row 2 · 2026-09-15 · Sale · Disposed 1,000 · Balance 0 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.54 to $73.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2028-07-08 | Direct | 103,077 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 1,000 · Balance 103,077 F3: Fully vested |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.54 to $73.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Fully vested
Fulgent Genetics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,000 |
Reported balance
After 2022-08-01 transaction · row 1
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 8,000 · Balance 8,000 F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.
uniQure N.V.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 35,494 |
Ending reported balance
After 2026-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-10 · Grant · Acquired 7,550 · Balance 37,487 F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Row 2 · 2026-06-11 · Sale · Disposed 1,993 · Balance 35,494 F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.82 · Expires 2036-06-10 | Direct | 13,980 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 13,980 · Balance 13,980 F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-26-394394 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $72.98 | $72,980.00 |
DisclosureSEC source: 0001193125-26-394394 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.54 to $73.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001193125-26-394394 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-26-355561 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $74.54 | $74,540.00 |
DisclosureSEC source: 0001193125-26-355561 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001193125-26-355561 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-26-307838 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $71.17 | $71,170.00 |
DisclosureSEC source: 0001193125-26-307838 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001193125-26-307838 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-26-282861 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,077 Underlying: Common Stock · 5,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 5,000 | $70.00 | $350,000.00 |
DisclosureSEC source: 0001193125-26-282861 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 5,000 | $0.60 | $3,000.00 |
DisclosureSEC source: 0001193125-26-282861 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-26-279543 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,077 Underlying: Common Stock · 5,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 5,000 | $65.00 | $325,000.00 |
DisclosureSEC source: 0001193125-26-279543 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 5,000 | $0.60 | $3,000.00 |
DisclosureSEC source: 0001193125-26-279543 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:38 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,993 | $27.06 | $53,930.58 |
DisclosureSEC source: 0000904454-26-000344 · edgar.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,494 F2 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:38 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 13,980 | $0.00 Strike: $26.82 | $0.00 |
DisclosureSEC source: 0000904454-26-000344 · edgar.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,980 Underlying: Ordinary Shares · 13,980 shares Expires 2036-06-10 F4 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:38 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-26-000344 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,487 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 9,354 | $0.00 Strike: $56.09 | $0.00 |
DisclosureSEC source: 0001193125-26-259705 · ownership.xml · derivative · entry 4 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,354 Underlying: Common Stock · 9,354 shares Expires 2036-06-03 F3 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-26-259705 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $54.50 | $54,500.00 |
DisclosureSEC source: 0001193125-26-259705 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026 Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001193125-26-259705 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026 Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-25-286228 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $41.43 | $41,430.00 |
DisclosureSEC source: 0001193125-25-286228 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001193125-25-286228 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-25-240271 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $43.25 | $43,250.00 |
DisclosureSEC source: 0001193125-25-240271 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001193125-25-240271 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-25-226964 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,077 Underlying: Common Stock · 5,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 5,000 | $40.09 | $200,450.00 |
DisclosureSEC source: 0001193125-25-226964 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 5,000 | $0.60 | $3,000.00 |
DisclosureSEC source: 0001193125-25-226964 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001193125-25-205003 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $35.10 | $35,100.00 |
DisclosureSEC source: 0001193125-25-205003 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001193125-25-205003 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001235862-25-000003 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $28.00 | $28,000.00 |
DisclosureSEC source: 0001235862-25-000003 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0001235862-25-000003 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-25-096949 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,077 Underlying: Common Stock · 2,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 2,000 | $28.00 | $56,000.00 |
DisclosureSEC source: 0000950170-25-096949 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 2,000 | $0.60 | $1,200.00 |
DisclosureSEC source: 0000950170-25-096949 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:03 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,112 | $14.45 | $30,518.40 |
DisclosureSEC source: 0000904454-25-000338 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,937 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.40 to $14.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:07 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,630 | $0.00 Strike: $16.22 | $0.00 |
DisclosureSEC source: 0000904454-25-000318 · edgar.xml · derivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Ordinary Shares · 15,630 shares Expires 2035-06-11 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:07 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,970 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-25-000318 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,049 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 24,165 | $0.00 Strike: $26.63 | $0.00 |
DisclosureSEC source: 0000950170-25-083240 · ownership.xml · derivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,165 Underlying: Common Stock · 24,165 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 5, 2025, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-25-076339 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $28.00 | $28,000.00 |
DisclosureSEC source: 0000950170-25-076339 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0000950170-25-076339 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2025 Filed Apr 29, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-25-060145 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| April 28, 2025 Filed Apr 29, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $30.76 | $30,760.00 |
DisclosureSEC source: 0000950170-25-060145 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| April 28, 2025 Filed Apr 29, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0000950170-25-060145 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.